These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 9670040)
21. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655 [TBL] [Abstract][Full Text] [Related]
22. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. Wagner SN; Wagner C; Lührs P; Weimann TK; Kutil R; Goos M; Stingl G; Schneeberger A J Invest Dermatol; 2000 Dec; 115(6):1082-7. PubMed ID: 11121145 [TBL] [Abstract][Full Text] [Related]
23. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
24. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity. Neal ZC; Bates MK; Albertini MR; Herweijer H Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322 [TBL] [Abstract][Full Text] [Related]
25. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538 [TBL] [Abstract][Full Text] [Related]
27. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. Yamanaka R; Xanthopoulos KG DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409 [TBL] [Abstract][Full Text] [Related]
28. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991 [TBL] [Abstract][Full Text] [Related]
29. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. Phan GQ; Touloukian CE; Yang JC; Restifo NP; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE; Rosenberg SA J Immunother; 2003; 26(4):349-56. PubMed ID: 12843797 [TBL] [Abstract][Full Text] [Related]
30. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
31. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632 [TBL] [Abstract][Full Text] [Related]
32. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. Touloukian CE; Leitner WW; Topalian SL; Li YF; Robbins PF; Rosenberg SA; Restifo NP J Immunol; 2000 Apr; 164(7):3535-42. PubMed ID: 10725708 [TBL] [Abstract][Full Text] [Related]
33. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866 [TBL] [Abstract][Full Text] [Related]
34. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471 [TBL] [Abstract][Full Text] [Related]
35. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222 [TBL] [Abstract][Full Text] [Related]
36. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4. Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858 [TBL] [Abstract][Full Text] [Related]
37. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients. Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353 [TBL] [Abstract][Full Text] [Related]
39. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Prins RM; Odesa SK; Liau LM Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014 [TBL] [Abstract][Full Text] [Related]
40. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]